Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Novavax Actually a Value Stock?

TheMotleyFool

0 0

You can accurately describe Novavax (NASDAQ: NVAX) in several ways. A huge winner? Definitely -- Novavax's shares are up over 4,300% since the beginning of 2020. A leader in the COVID-19 vaccine race? Sure: The company could win Emergency Use Authorization (EUA) for its NVX-CoV2373 vaccine this summer.

There's one description of Novavax, though, that many investors might shy away from. Probably few would refer to the biotech as a value stock. After all, Novavax's market cap is close to $13 billion, with no product even on the market yet. However, there is a case to be made that Novavax actually is a value stock.

Image source: Getty Images.

Source Fool.com

Like: 0

NVAX

Share